サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790245

米国の創薬アウトソーシング市場規模、シェア、動向分析レポート：ワークフロー別、薬剤別、サービス別、治療分野別、最終用途別、セグメント予測、2025年～203年

U.S. Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow, By Drug, By Service, By Therapeutics Area, By End Use, And Segment Forecasts, 2025 - 203

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
米国の創薬アウトソーシング市場規模、シェア、動向分析レポート：ワークフロー別、薬剤別、サービス別、治療分野別、最終用途別、セグメント予測、2025年～203年
出版日: 2025年07月14日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向

米国の創薬アウトソーシング市場規模は2024年に24億9,000万米ドルと推定され、2025～2033年にかけてCAGR 9.52％で成長すると予測されます。

創薬アウトソーシング市場を牽引しているのは、新薬候補に対する需要の高まり、慢性疾患の罹患率の上昇、研究開発費の増加、新たな官民パートナーシップの構築、専門知識の必要性、複雑な標的治療の増加などがあります。

また、バイオ医薬品・製薬企業の多くは、人工知能、バイオインフォマティクス、高性能スクリーニングなどの先端技術を活用するため、CROやCDMOを利用するようになっています。加えて、社内に強固な能力を持たない小規模バーチャルなバイオテクノロジー企業が増加していることも、アウトソーシングの動向をさらに加速させています。

さらに、個別化医療や適応性の高い開発フレームワークへの移行動向も、創薬サービスのアウトソーシング需要を高めています。グローバリゼーション、IND申請までの期間短縮の必要性、新たな治療領域の出現は、成長のための重要な戦略としてアウトソーシングを継続的に後押ししています。

さらに、個別化医療の台頭が、米国の創薬アウトソーシング部門における適応性の高い少量生産の必要性を高めています。特に腫瘍学、希少疾患、遺伝子治療などの領域で治療の標的が絞られるにつれ、従来型大量生産方式はカスタマイズ型医薬品開発戦略へと移行しつつあり、これが推定期間中の市場成長を促進すると予想されます。

開発業務受託機関（CRO）や研究開発業務受託機関（CDRO）は、モジュール化されたインフラ、柔軟なワークフロー、迅速なアッセイ開発を活用し、重要なパートナーとなっています。アウトソーシングにより、バイオ製薬企業は、薬剤設計、患者層別化、バイオマーカー主導型研究におけるばらつきを調整する能力を得ることができ、その結果、高精度治療の市場投入における敏捷性、費用対効果、スピードが向上します。

さらに、創薬における人工知能（AI）と機械学習（ML）の統合の進展は、化合物の同定、最適化、検証のプロセスを変革しつつあります。AIは標的同定を合理化し、薬剤類似性を評価し、分子間相互作用をモデル化することで、初期段階の研究開発のタイムラインと経費を大幅に削減します。さらに、MLアルゴリズムは、オミクスデータから臨床結果に至る広範なデータセットをふるいにかけ、革新的な洞察を明らかにし、候補化合物選択におけるリスクを最小化します。

さらに、米国のバイオ製薬企業は、生産性を高め、治験薬（IND）申請までの道のりを加速し、複雑な疾患や希少疾患の治療開発の成功率を高めるために、AIを活用したソリューションをワークフローに取り入れたり、AIに特化した医薬品開発業務受託機関（CRO）と連携したりする動きが加速しています。例えば、2024年7月、Exscientia plcは、クラウドプロバイダのAI＆MLサービスを利用して、エンドツーエンドの創薬と自動化のための同社のプラットフォームを強化するため、Amazon Web Servicesの拡大に言及しました。このような要因が推定期間を牽引すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の創薬アウトソーシング市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 臨床検査件数分析（2024年）
    • 地域別臨床検査総数
    • 臨床検査の総数（相別）
    • 臨床検査の総数（研究デザイン別）
    • 主要治療領域別臨床検査総数
  • 価格モデル分析
  • 技術
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • SWOT分析によるPESTEL
    • COVID-19の影響分析

第4章 米国の創薬アウトソーシング市場：ワークフロー別、推定・動向分析

  • 米国の創薬アウトソーシング市場（ワークフロー別）：セグメントダッシュボード
  • 米国の創薬アウトソーシング市場（ワークフロー別）：変動分析
  • ワークフロー別、2021～2033年
  • 対象の特定とスクリーニング
  • 対象検証と機能情報科学
  • リード特定と候補者最適化
  • 前臨床開発
  • その他

第5章 米国の創薬アウトソーシング市場：薬剤別、推定・動向分析

  • 米国の創薬アウトソーシング市場（薬剤別）：セグメントダッシュボード
  • 米国の創薬アウトソーシング市場（薬剤別）：変動分析
  • 薬剤別、2021～2033年
  • 小分子
  • 巨大分子

第6章 米国の創薬アウトソーシング市場：サービス別、推定・動向分析

  • 米国の創薬アウトソーシング市場（サービス別）：セグメントダッシュボード
  • 米国の創薬アウトソーシング市場（サービス別）：変動分析
  • サービス別、2021～2033年
  • 化学サービス
  • 生物サービス

第7章 米国の創薬アウトソーシング市場：治療分野別、推定・動向分析

  • 米国の創薬アウトソーシング市場（治療分野別）：セグメントダッシュボード
  • 米国の創薬アウトソーシング市場（治療分野別）：変動分析
  • 治療分野別、2021～2033年
  • 呼吸器系
  • 痛みと麻酔
  • 腫瘍学
  • 眼科
  • 血液学
  • 心血管系
  • 内分泌
  • 胃腸
  • 免疫調節
  • 抗感染性
  • 中枢神経系
  • 皮膚科
  • 泌尿生殖器系

第8章 米国の創薬アウトソーシング市場：最終用途別、推定・動向分析

  • 米国の創薬アウトソーシング市場（最終用途別）：セグメントダッシュボード
  • 米国の創薬アウトソーシング市場（最終用途別）：変動分析
  • 最終用途別、2021～2033年
  • 製薬バイオテクノロジー企業
  • 学術機関

第9章 競合情勢

  • 市場参入企業の分類
  • 企業市場シェア/評価分析、2024年
  • 企業プロファイル
    • Albany Molecular Research Inc.
    • EVOTEC
    • Laboratory Corporation of America Holdings
    • GenScript
    • Pharmaceutical Product Development, LLC
    • Charles River Laboratories
    • WuXi AppTec
    • Thermo Fisher Scientific Inc.
    • Dalton Pharma Services
    • Oncodesign
    • Jubilant Biosys
    • DiscoverX Corp.
    • QIAGEN
    • Eurofins SE
    • Syngene International Limited
    • Dr. Reddy Laboratories Ltd.
    • Pharmaron Beijing Co., Ltd.
    • TCG Lifesciences Pvt Ltd.
    • Domainex Ltd.

第10章 主要推奨事項

図表

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
  • Table 5 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
  • Table 6 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 7 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 8 U.S. Drug Discovery Outsourcing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Drug Discovery Outsourcing Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Drug Discovery Outsourcing Market: Workflow outlook and key takeaways
  • Fig. 20 U.S. Drug Discovery Outsourcing Market: Workflow movement analysis
  • Fig. 21 Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. Drug Discovery Outsourcing Market: Drug outlook and key takeaways
  • Fig. 27 U.S. Drug Discovery Outsourcing Market: Drug movement analysis
  • Fig. 28 Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Drug Discovery Outsourcing Market: Service outlook and key takeaways
  • Fig. 31 U.S. Drug Discovery Outsourcing Market: Service movement analysis
  • Fig. 32 Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Drug Discovery Outsourcing Market: Therapeutics Area outlook and key takeaways
  • Fig. 35 U.S. Drug Discovery Outsourcing Market: Therapeutics Area movement analysis
  • Fig. 36 Respiratory system Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Central NervoU.S. System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 U.S. Drug Discovery Outsourcing Market: End Use outlook and key takeaways
  • Fig. 50 U.S. Drug Discovery Outsourcing Market: End Use movement analysis
  • Fig. 51 Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key company categorization
  • Fig. 54 Service heat map analysis
  • Fig. 55 Strategic framework
目次
Product Code: GVR-4-68040-281-9

Market Size & Trends:

The U.S. drug discovery outsourcing market size was estimated at USD 2.49 billion in 2024 and is projected to grow at a CAGR of 9.52% from 2025 to 2033. The market for drug discovery outsourcing is driven by growing demand for novel drug candidates, rising incidence of chronic diseases, increasing R&D expenditures, emerging new private-public partnerships, a need for specialized knowledge, and a growing array of complex and targeted therapies.

Besides, most of the biopharmaceutical and pharmaceutical companies are turning to CROs and CDMOs to leverage advanced technologies such as artificial intelligence, bioinformatics, and high-throughput screening. In addition, the rising number of small and virtual biotech companies, which often lack robust internal capabilities, further accelerates the trend toward outsourcing.

Moreover, shifting trends towards personalized medicine and adaptable development frameworks enhances the demand for outsourced discovery services. Globalization, the need for quicker time-to-IND submissions, and the emergence of new therapeutic areas are continuously driving outsourcing as a key strategy for growth.

In addition, the emergence of personalized medicine is driving the need for adaptable, small-batch production within the U.S. drug discovery outsourcing sector. As treatments become increasingly targeted, particularly in areas like oncology, rare diseases, and gene therapy, traditional mass production methods are shifting towards customized drug development strategies, which are expected to drive the market growth over the estimated time period.

Contract research organizations (CROs) and contract development and research organizations (CDROs) utilize a modular infrastructure, flexible workflows, and quick assay development are becoming vital partners. Outsourcing provides biopharma companies with the ability to navigate variability in drug design, patient stratification, and biomarker-driven studies, which in turn enhances their agility, cost-effectiveness, and speed in bringing precision therapies to market.

Furthermore, the growing integration of artificial intelligence (AI) and machine learning (ML) in drug discovery is transforming the process of identifying, optimizing, and validating compounds. AI streamlines target identification, assesses drug-likeness, and models molecular interactions, leading to significant reductions in early-stage R&D timelines and expenses. Besides, ML algorithms sift through extensive datasets ranging from omics data to clinical outcomes to reveal innovative insights and minimize risks in candidate selection.

In addition, biopharma companies in the U.S. are increasingly incorporating AI-driven solutions into their workflows or collaborating with AI-focused contract research organizations (CROs) to boost productivity, accelerate the path to Investigational New Drug (IND) applications, and enhance success rates in the development of treatments for complex and rare diseases. For instance, in July 2024, Exscientia plc mentioned Amazon Web Services expansion to use the AI & ML services of cloud providers to power the company's platform for end-to-end drug discovery and automation. Such factors are expected to drive the estimated time period.

U.S. Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. drug discovery outsourcing market report based on workflow, drug, service, therapeutics area, end use, and country.

  • Workflow Outlook (Revenue, USD Million, 2021 - 2033)
  • Target Identification & Screening
  • Target Validation & Functional Informatics
  • Lead Identification & Candidate Optimization
  • Preclinical Development
  • Others
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Molecules
  • Large Molecules
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemistry Services
  • Biology Services
  • Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Respiratory system
  • Pain and Anesthesia
  • Oncology
  • Ophthalmology
  • Hematology
  • Cardiovascular
  • Endocrine
  • Gastrointestinal
  • Immunomodulation
  • Anti-infective
  • Central Nervous System
  • Dermatology
  • Genitourinary System
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology companies
  • Academic Institutes

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Workflow
    • 1.2.2. Drug
    • 1.2.3. Service
    • 1.2.4. Therapeutics Area
    • 1.2.5. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Value chain-based analysis
    • 1.7.3. Multivariate Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Drug Discovery Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising R&D cost in biopharmaceutical Industry
      • 3.2.1.2. Increasing access to specialized expertise
      • 3.2.1.3. Growing demand for outsourcing Services in Drug Development
      • 3.2.1.4. Increasing number of partnerships in U.S. Drug Discovery research
      • 3.2.1.5. Technological advancements in drug discovery
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of open-source software packages for drug discovery
      • 3.2.2.2. High manufacturing costs coupled with high risk of drug failure
      • 3.2.2.3. Rising Data Security and IP Concerns
      • 3.2.2.4. Regulatory and Compliance Risks
  • 3.3. Clinical Trials Volume Analysis (2024)
    • 3.3.1. Total Number of Clinical Trials, By Region
    • 3.3.2. Total Number of Clinical Trials, By Phase
    • 3.3.3. Total Number of Clinical Trials, By Study Design
    • 3.3.4. Total Number of Clinical Trials, By Key Therapeutic Area
  • 3.4. Pricing Model Analysis
  • 3.5. Technology Landscape
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Force Analysis
    • 3.6.2. PESTEL by SWOT Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. U.S. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

  • 4.1. U.S. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
  • 4.2. U.S. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
  • 4.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
  • 4.4. Target Identification & Screening
    • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Target Validation & Functional Informatics
    • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Lead Identification & Candidate Optimization
    • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Preclinical Development
    • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Drug Discovery Outsourcing Market: Drug Estimates & Trend Analysis

  • 5.1. U.S. Drug Discovery Outsourcing Market, By Drug: Segment Dashboard
  • 5.2. U.S. Drug Discovery Outsourcing Market, By Drug: Movement Analysis
  • 5.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug, 2021 - 2033 (USD Million)
  • 5.4. Small Molecules
    • 5.4.1. Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Large Molecules
    • 5.5.1. Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

  • 6.1. U.S. Drug Discovery Outsourcing Market, By Service: Segment Dashboard
  • 6.2. U.S. Drug Discovery Outsourcing Market, By Service: Movement Analysis
  • 6.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
  • 6.4. Chemistry Services
    • 6.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Biology Services
    • 6.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

  • 7.1. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
  • 7.2. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
  • 7.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
  • 7.4. Respiratory system
    • 7.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Pain and Anesthesia
    • 7.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Oncology
    • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Ophthalmology
    • 7.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Hematology
    • 7.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Cardiovascular
    • 7.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Endocrine
    • 7.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Gastrointestinal
    • 7.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.12. Immunomodulation
    • 7.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.13. Anti-infective
    • 7.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.14. Central Nervous System
    • 7.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.15. Dermatology
    • 7.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.16. Genitourinary System
    • 7.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

  • 8.1. U.S. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
  • 8.2. U.S. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
  • 8.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 8.4. Pharmaceutical & Biotechnology companies
    • 8.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Academic Institutes
    • 8.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Share/Assessment Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. Albany Molecular Research Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. EVOTEC
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Laboratory Corporation of America Holdings
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. GenScript
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Pharmaceutical Product Development, LLC
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Charles River Laboratories
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. WuXi AppTec
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Thermo Fisher Scientific Inc.
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Dalton Pharma Services
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Oncodesign
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Jubilant Biosys
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. DiscoverX Corp.
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. QIAGEN
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Eurofins SE
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Service Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. Syngene International Limited
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Financial Performance
      • 9.3.15.3. Service Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. Dr. Reddy Laboratories Ltd.
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Financial Performance
      • 9.3.16.3. Service Benchmarking
      • 9.3.16.4. Strategic Initiatives
    • 9.3.17. Pharmaron Beijing Co., Ltd.
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Financial Performance
      • 9.3.17.3. Service Benchmarking
      • 9.3.17.4. Strategic Initiatives
    • 9.3.18. TCG Lifesciences Pvt Ltd.
      • 9.3.18.1. Company Overview
      • 9.3.18.2. Financial Performance
      • 9.3.18.3. Service Benchmarking
      • 9.3.18.4. Strategic Initiatives
    • 9.3.19. Domainex Ltd.
      • 9.3.19.1. Company Overview
      • 9.3.19.2. Financial Performance
      • 9.3.19.3. Service Benchmarking
      • 9.3.19.4. Strategic Initiatives

Chapter 10. Key Recommendations